Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
International Eye Science ; (12): 1293-1295, 2015.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-637476

RESUMO

AlM:To observe clinical effects between the laser in situ keratomileusis ( LASlK ) surgery and the laser subepithelial keratomileusis ( LASEK ) surgery as the second operation after an unsuccessful LASlK surgery.METHODS:Forty-nine patients (98 eyes) with refractive regression after LASlK operation received the second surgery. All patients were divided into two groups:group A and B. Group A (48 eyes of 24 patients) received LASlK surgery and group B ( 50 eyes of 25 patients ) received LASEK surgery. lnspect the main parameters included visual acuity, refraction, corneal curvature, and the total value of high-aberration after 1wk, 1mo and 1a, t-test of groups was used as statistical analysis method.RESULTS: There was statistically significant (P0. 05). There developed one case of epithelium in growth after LASlK surgery, and one case of haze Ⅱ after LASEK surgery.CONCLUSlON: Both LASlK and LASEK surgery can obtain satisfactory therapeutic results after an unsuccessful LASlK surgery.

2.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-813939

RESUMO

OBJECTIVE@#To observe the effect of FTY720 and ICAM-1 mAb mono and combination therapy in mouse-to-rat cardiac xenotransplantation.@*METHODS@#Cardiac xenotransplantation was performed in abdominal site with micro-surgical technique. Recipients with xenografts were treated with different doses of FTY720 and/or ICAM-1 mAb. Graft survival, histopathology, infiltration of CD4+, and CD8+ T cells and levels of serum IL-2, IFN-gamma, IL-4, and IgM were investigated.@*RESULTS@#Survival time of xenografts was (2.75+/- 0.43)d in the controls, survival of grafts treated with ICAM-1 mAb did not significantly improve. Treatment with large dose FTY720 led to a survival of (4.25+/- 0.71)d (P<0.01). Combination therapy with large dose FTY720 and ICAM-1 mAb achieved a significant prolongation of graft survival with (10.25+/- 2.12)d (P<0.01). Levels of serum IL-2, IFN-gamma and rat-anti-mouse IgM decreased in the combined therapy group. Pathologic lesion and infiltration of T cells in xenografts showed mitigated in the large dose combined therapy group. There was a significant negative correlation between the antibody level and the graft survival time (R=-0.754, P<0.01).@*CONCLUSION@#The combined therapy of FTY720 and ICAM-1 mAb can achieve a significant effect in the prolongation of heart xenograft survival and inhibition of xenoantibodies.


Assuntos
Animais , Feminino , Camundongos , Ratos , Anticorpos Monoclonais , Usos Terapêuticos , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Cloridrato de Fingolimode , Rejeição de Enxerto , Sangue , Sobrevivência de Enxerto , Transplante de Coração , Métodos , Imunoglobulina M , Sangue , Imunossupressores , Usos Terapêuticos , Molécula 1 de Adesão Intercelular , Alergia e Imunologia , Interferon gama , Sangue , Interleucina-2 , Sangue , Interleucina-4 , Sangue , Camundongos Endogâmicos BALB C , Propilenoglicóis , Usos Terapêuticos , Ratos Wistar , Esfingosina , Usos Terapêuticos , Fatores de Tempo , Transplante Heterólogo
3.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-813938

RESUMO

OBJECTIVE@#To explore the role of combined heart-thymus transplantation for heart allograft in rats.@*METHODS@#Vascularized heart-thymus combined transplantation was performed with microsurgical technique. Graft survival, histopathology, infiltration of CD4+, CD8+ T cells, level and mRNA expressions of IL-2 and IL-4 in the serum and cardiac grafts were investigated.@*RESULTS@#Heart allograft in the controls had a survival time of (6.0+/-0.76) d. heart-thymus combined transplantation in non-thymectomized rats had a survival time of (6.88+/-0.64)d (P<0.05). Heart-thymus combined transplantation in thymectomized rats led to an evident survival time of (14.13+/-5.82)d (P<0.01) for cardiac graft, which further obtained long term survival after short course of treatment with cyclosporine. Pathologic lesion and infiltration of CD4+ and CD8+ T cells in cardiac grafts showed mitigated in the long term survival group. IL-2 level in the serum and cardiac grafts maintained low level in the long term survival group, whereas IL-4 maintained high level.@*CONCLUSION@#Whether thymectomized or not in recipient rats, heart-thymus combined transplantation has a positive effect to protect cardiac graft. Furthermore, in thymectomized rats heart-thymus combined transplantation may lead to evident survival prolongation of the heart grafts, which induces immune tolerance in short course of treatment with cyclosporine.


Assuntos
Animais , Masculino , Ratos , Linfócitos T CD4-Positivos , Alergia e Imunologia , Linfócitos T CD8-Positivos , Alergia e Imunologia , Ciclosporina , Usos Terapêuticos , Sobrevivência de Enxerto , Alergia e Imunologia , Transplante de Coração , Tolerância Imunológica , Alergia e Imunologia , Imunossupressores , Usos Terapêuticos , Interleucina-2 , Sangue , Genética , Interleucina-4 , Sangue , Genética , Ratos Sprague-Dawley , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Timectomia , Timo , Transplante , Fatores de Tempo , Imunologia de Transplantes , Alergia e Imunologia , Transplante Homólogo
4.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-813760

RESUMO

OBJECTIVE@#To explore the role of allo heart and thymus transplantation by intrathymic inoculation of thymocytes.@*METHODS@#Wistar recipients were given intrathymic injection of allo thymocytes (2 x 10(7)) 14 days before the heart and/or thymus transplantation. Graft survival, histopathology, levels and mRNA expressions of IL-2, IL-4 in serum and cardiac-grafts were investigated.@*RESULTS@#Heart transplantation and heart-thymus composite transplantation with the treatment of CysA for 7 or 14 days prolonged graft survival. Heart transplantation and heart-thymus composite transplantation with intrathymic thymocytes injection induced the long-term survival of allo-grafts transiently immunosuppressed with CysA; IL-4 maintained at high levels but IL-2 kept at low levels in grafts in long-term survivals.@*CONCLUSION@#Intrathymic inoculation of allo thymoctyes can induce immune tolerance for both cardiac transplantation and heart-thymus combined transplantation in rats. Thymus graft may play a role in the induction and maintenance of central tolerance.


Assuntos
Animais , Feminino , Ratos , Transplante de Células , Rejeição de Enxerto , Sobrevivência de Enxerto , Transplante de Coração , Tolerância Imunológica , Interleucina-2 , Sangue , Interleucina-4 , Sangue , Ratos Sprague-Dawley , Ratos Wistar , Timo , Biologia Celular , Transplante
5.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-813508

RESUMO

OBJECTIVE@#To observe the effect of cyclosporine and simulect mono or combination therapy on cardiac allo-transplantation in rats.@*METHODS@#Recipients with allografts were treated with different doses of cyclosporine and/or simulect after cardiac allo-transplantation. Graft survival time was observed; the histopathological examination of graft tissues was performed; and levels of serum IL-2 and IL-4 were determined.@*RESULTS@#Mono or combination therapy with cyclosporine and/or simulect increased the survival of cardiac allografts. With the prolongation of survival time of the grafts, the rejection of grafts was moderated. The serum IL-2 level increased in acute rejected grafts; the serum IL-4 level increased evidently in long survival grafts.@*CONCLUSION@#Cyclosporine and simulect have an effect in the prolongation of cardiac allograft survival in rats, and the combination therapy shows an evident synergistic effect.


Assuntos
Animais , Feminino , Ratos , Anticorpos Monoclonais , Farmacologia , Usos Terapêuticos , Basiliximab , Terapia Combinada , Ciclosporina , Farmacologia , Usos Terapêuticos , Rejeição de Enxerto , Alergia e Imunologia , Transplante de Coração , Imunossupressores , Farmacologia , Usos Terapêuticos , Ratos Sprague-Dawley , Ratos Wistar , Proteínas Recombinantes de Fusão , Farmacologia , Usos Terapêuticos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...